Alexion Pharmaceuticals Inc. (ALXN)
Symbol Info
Listed Symbol ALXN
Name Alexion Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $4,130,100,000
Latest Fiscal EPS $0.33
Price Info
21 Day Moving Average $99.4376
21 Day EMA $100.411900
50 Day Moving Average $104.6414
50 Day EMA $104.663930
200 Day EMA $116.020060
200 Day Moving Average 120.347800
52 Week High $141.86
52 Week Low $92.56
52 Week Change $-22.242400
Alpha -0.016964
Beta 1.6470
Standard Deviation 0.107118
R2 0.278814
Periods 60
Share Information
10 Day Average Volume 1,660,537
20 Day Average Volume 1,691,568
30 Day Average Volume 1,939,340
50 Day Average Volume 2,399,891
Outstanding Shares 224,226,878
Float Shares 221,767,399
Percent Float 98.90%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 1,388
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 16,007,232
Institute Holdings Percent -
Institute Sold Previous 3 Months 23,670,740
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months -
Insider Holdings Percent 1.10%
Insider Sold Previous 3 Months 7
Insiders Shares Owned 2,459,479
Price Change
7 Day Price Change $-0.8399963
7 Day Percent Change -0.85%
21 Day Price Change $0.6400070
21 Day Percent Change 0.65%
30 Day Price Change $-4.5699997
30 Day Percent Change -4.44%
Month To Date Price Change $0.4700
Month To Date Percent 0.48%
90 Day Price Change $-24.849998
90 Day Percent Change -20.16%
Quarter To Date $0.470001
Quarter To Date Percent 0.48%
180 Day Price Change $-27.599998
180 Day Percent Change -21.90%
200 Day Price Change $-36.910004
200 Day Percent Change -27.28%
Year To Date $1.050003
Year To Date Percent 1.08%
Profile
Description Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis. Next-generation Ultomiris was recently approved in paroxysmal nocturnal hemoglobinuria. Strensiq and Kanuma target other ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need and complement-mediated disorders.
Details
Issue Type CS
Market Cap $22,066,167,064
Sec Type EQS
Auditor PricewaterhouseCoopers LLP
Total Shares Outstanding 224,226,878
CEO Ludwig N. Hantson
Employees 2,656
Last Audit UQ
Classification
CIK 0000899866
Industry Biotechnology
Sector Healthcare
NAICS Research and Development in Biotechnology (except Nanobiotechnology)(541714)
Info
Address 121 Seaport Boulevard
Boston, MA 2210
Website http://www.alexion.com
Facisimile +1 203 271-8198
Telephone +1 475-230-2596
Email
Key Ratios
Profitability
EBIT Margin 32.00
EBITDA Margin 40.8
Pre-Tax Profit Margin 19.6
Profit Margin Cont 28.89
Gross Margin 91.70
Profit Margin TOT 28.89
Income Statements
Revenue $3,471,200,000
Revenue Per Share $15.4807
Revenue 3 Years $7.87
Revenue 5 Years $12.93
Valuation Measures
PE Ratio 16.50
Enterprise Value $22,601,580,431
Price To Sales 6.356928
Price To Free Cash 23.800000
PE High Last 5 Years 251.2
Price To Book 2.2
Price To Cash Flow 15.3
PE Low Last 5 Years 43.6
Price To Tangible Book 13.3
Financial Strength
Total Debt To Equity 0.3
Int Coverage 16.5
Current Ratio 4.0
Leverage Ratio 1.4
Quick Ratio 3.1
Long Term Debt To Capital 0.20
Assets
Receivables Turnover 1.6
Invoice Turnover 0.60
Assets Turnover 0.10
Management Effectiveness
Return Assets 9.51
Return On Equity 14.09
Return On Capital 11.42
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
ALXN
Alexion Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.